However, there was no significant difference in the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic DMARDs between AOSD patients with and without anti-IFN-γ autoAbs. This evidence concerns the gene IFNG and adult-onset Still disease.